Diarrhea Treatment Pipeline Review H2 2016

PUNE, INDIA, August 30, 2016 /EINPresswire.com/ -- Summary
‘Diarrhea - Pipeline Review, H2 2016’, provides an overview of the Diarrhea pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Diarrhea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diarrhea and features dormant and discontinued projects.

Complete report details @ https://www.wiseguyreports.com/reports/619278-diarrhea-pipeline-review-h2-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Request a sample report @ https://www.wiseguyreports.com/sample-request/619278-diarrhea-pipeline-review-h2-2016

Scope
- The report provides a snapshot of the global therapeutic landscape of Diarrhea
- The report reviews pipeline therapeutics for Diarrhea by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Diarrhea therapeutics and enlists all their major and minor projects
- The report assesses Diarrhea therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Diarrhea
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Diarrhea
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Diarrhea pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @ https://www.wiseguyreports.com/enquiry/619278-diarrhea-pipeline-review-h2-2016

Key points in table of content
Table of Contents
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Diarrhea Overview 8
Therapeutics Development 9
Pipeline Products for Diarrhea - Overview 9
Pipeline Products for Diarrhea - Comparative Analysis 10
Diarrhea - Therapeutics under Development by Companies 11
Diarrhea - Therapeutics under Investigation by Universities/Institutes 13
Diarrhea - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Diarrhea - Products under Development by Companies 17
Diarrhea - Products under Investigation by Universities/Institutes 20
Diarrhea - Companies Involved in Therapeutics Development 21
A. Menarini Industrie Farmaceutiche Riunite Srl 21
Ache Laboratorios Farmaceuticos S/A 22
Actelion Ltd 23
Aegis Therapeutics, LLC 24
AlbireoPharma 25
Allergan Plc 26
Anatara Lifesciences Limited 27
Ardelyx, Inc. 28
Assembly Biosciences, Inc. 29
Codagenix, Inc. 30
Cosmo Pharmaceuticals S.p.A 31
DesignMedix, Inc. 32
DiscoveryBiomed, Inc. 33
Genextra S.p.a. 34
GlaxoSmithKline Plc 35
GP Pharm, S.A. 36
Mucosis B.V. 37
Nippon Shinyaku Co., Ltd. 38
Novartis AG 39
Pfizer Inc. 40
Prokarium Limited 41
Protagonist Therapeutics Inc. 42
Rebiotix Inc. 43
Recce Pty Ltd 44
RxBio, Inc. 45
Scandinavian Biopharma Holding AB 46
Sigmoid Pharma Limited 47
Summit Therapeutics Plc 48
Synthetic Biologics, Inc. 49
Syntiron LLC 50
Tasly Pharmaceutical Group Co., Ltd. 51
Diarrhea - Therapeutics Assessment 52
Assessment by Monotherapy Products 52
Assessment by Target 53
Assessment by Mechanism of Action 56
Assessment by Route of Administration 59
Assessment by Molecule Type 61
Drug Profiles 63
ABM-101 - Drug Profile 63
ACH-04 - Drug Profile 64
ASP-7147 - Drug Profile 65
cadazolid - Drug Profile 66
Campylobacter jejuni [strain CPS81-176] vaccine - Drug Profile 68
cholestyramine - Drug Profile 70
Clostridium difficile vaccine - Drug Profile 71
crofelemer DR - Drug Profile 72
Drug for Diarrhea - Drug Profile 75
eluxadoline - Drug Profile 76
Escherichia coli vaccine - Drug Profile 80
ETEC vaccine - Drug Profile 81
ETEC vaccine - Drug Profile 82
Etvax - Drug Profile 83
GVXNSD-133 - Drug Profile 85
GXG-8 - Drug Profile 86
ibodutant - Drug Profile 87
IMSUTMR-1501 - Drug Profile 88
infectious diarrhea [serotype H11] vaccine - Drug Profile 89
LJN-452 - Drug Profile 90
obeticholic acid - Drug Profile 91
octreotide acetate - Drug Profile 102
octreotide acetate MAR - Drug Profile 103

Buy this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=619278

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here